Chitosan−Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY)

Li, Xiaoyu; Jin, Lei; McAllister, Tim A.; Stanford, Kim; Xu, Jie; Lu, Yuele; Zhen, Yuhong; Sun, Yongxin; Xu, Yongping

doi:10.1021/jf062900q

Cited by 98 publications

(72 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specific IgY against K88+ ETEC was prepared and purified as described previously [3]. IgY powder was obtained by freeze-drying and its purity was determined to be over 82% based on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Chitosan–Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY): Effects of Chitosan Concentration

Jin

et al. 2009

Appl Biochem Biotechnol

Self Cite

View full text Add to dashboard Cite

In our previous study, chitosan-alginate microcapsules were developed to protect egg yolk immunoglobulin (IgY) from gastric inactivation. The present study was undertaken to determine the effect of chitosan concentration (0-0.8%; w/v) on various properties of the microcapsules in order to produce the optimum chitosan-alginate microcapsules for use in the oral delivery of IgY. The properties investigated included microcapsule morphology, loading capacity for IgY (expressed as the IgY loading percentage, w/w, of microcapsules), encapsulation efficiency (EE%), in vitro gastroresistance, and IgY release. IgY loading percentage and EE% were both highest at 0.2% (w/v) chitosan, and, above this level, further increases were not observed. The stability of IgY in simulated gastric fluid (pH 1.2) was significantly improved by encapsulation in alginate microcapsules (IgY retained 43.5% of its activity) and was further improved by including chitosan at any of the chitosan concentrations assessed (IgY retained an average of 69.4% activity) although there was no difference in protection of gastric inactivation among concentrations of chitosan varying from 0.05% to 0.8% (w/v). Higher chitosan concentrations (i.e., >/=0.2%; w/v) prolonged the release of IgY from the microcapsules during simulated intestinal fluid incubation (pH 6.8). However, above the 0.2% (w/v) level, no significant differences were observed. We conclude that the optimum chitosan concentration for microencapsulation is 0.2% (w/v).

show abstract

Section: Methodsmentioning

confidence: 99%

“…In our previous study, the applicability of chitosan-alginate microcapsules for oral delivery of IgY was established [3]. We showed that chitosan-alginate microcapsulation enabled a larger proportion of the IgY to remain bioactive in a simulated gastrointestinal tract environment providing an effective delivery system for specific IgY.…”

Section: Introductionmentioning

confidence: 99%

Chitosan–Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY): Effects of Chitosan Concentration

Jin

et al. 2009

Appl Biochem Biotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The use of chitosan-alginate microcapsules to protect IgY from gastrointestinal environment conditions provides significant resistance to pepsin hydrolysis and may enable intact IgY to reach target microorganisms within the lower digestive tract [78]. Another approach protecting IgY from degradation in gastric pH can be the incorporation of antibodies to hydrogel containing acrylamide and acrylic acid with promising results for IgY oral delivery [79].…”

Section: Using Igy For Passive Immunizationmentioning

confidence: 99%

IgY-Technology Applied to Studies of Toxoplasma gondii Infection

Júnior¹,

Santos²,

Bassi³

et al. 2017

Toxoplasmosis

View full text Add to dashboard Cite

In this chapter, we describe relevant aspects of immunoglobulin Y (IgY) technology for Toxoplasma gondii applications, including comparison of avian IgY antibody with mammalian IgG antibody, egg yolk IgY production and isolation procedures, important applications for IgY antibody, and state of the art and perspectives for IgY-technology in T. gondii studies. T. gondii is a worldwide public health problem. IgY-technology provides an alternative antibody (IgY) to mammalian Immunoglobulin G (IgG) antibody. IgY-technology involves the chicken immunization, yolk IgY isolation, antibody characterization, and purified IgY application to several kinds of methods. Immunized chicken transfers a specific IgY from blood to egg yolk. Phylogenetic distance between chickens and mammals influences the generation of antibody repertoires recognizing an antigen profile. IgY is not bound to rheumatoid factor or mammalian complement protein and thus avoids the false-positive results. Yolk IgY isolation is carried out by simple procedures that are accessible for any laboratory and, also, for IgY isolation at large-scale production. IgY-technology provides antibodies for proteomic studies, diagnostic assays, and immunotherapy. Although IgY-technology is promising, there is a reduced number of investigations with IgY and T. gondii. Future perspectives involve the use of IgY-technology for the screening of new T. gondii antigens for diagnostics, therapy, or vaccine, development of innovative techniques for toxoplasmosis diagnostics and may be an immunotherapy for toxoplasmosis.

show abstract

“…The method was modified from Li et al (2007). IgY retention was expressed as the percentage of total available IgY in the microcapsules.…”

Section: Determination Of Igy Retentionmentioning

confidence: 99%

Influence of Chitosan-Alginate Microcapsules Containing Anti-Vibrio Harveyi IgY in the Gastrointestinal Tract Simulation

Punyokun¹,

Hongprayoon²,

Srisapoome³

et al. 2015

MAS

View full text Add to dashboard Cite

Egg yolk immunoglobulin (IgY) is an alternative treatment for the prevention of gastrointestinal infections in pigs, cows, chickens and fish. In our previous report, we preliminarily proved that anti-V. harveyi IgY had effective potential to control luminous disease in black tiger shrimp. However, IgY activity may be reduced or destroyed by gastric conditions, particularly low pH and digestive enzymes. Therefore, it is necessary to find an effective method to preserve the therapeutic function of IgY antibodies during gastric passage. Chitosan-alginate microcapsules have been developed to protect IgY from gastric inactivation. The processing factors included different forms of chitosan and alginate, while a CaCl2 concentration and encapsulation medium was investigated. The optimum results were obtained under the following conditions: High Mw chitosan concentration 0.2% (w/v), medium viscosity alginate concentration 2% (w/v), CaCl2 concentration 0.5% (w/v). The stability of IgY in simulated gastric fluid (SGF, pH 1.2) was greatly improved by encapsulation in chitosan-alginate microcapsules, and retained greater than 90% activity after 2 h exposure to SGF. Less than 10% IgY was released upon the microcapsules' exposure to SGF for 2 h, and more than 80% IgY was released upon the microcapsules' exposure to simulated intestinal fluid (SIF, pH 6.8) for 16 h.

show abstract

Chitosan−Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY)

Cited by 98 publications

References 25 publications

Chitosan–Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY): Effects of Chitosan Concentration

Chitosan–Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY): Effects of Chitosan Concentration

IgY-Technology Applied to Studies of Toxoplasma gondii Infection

Influence of Chitosan-Alginate Microcapsules Containing Anti-Vibrio Harveyi IgY in the Gastrointestinal Tract Simulation

Contact Info

Product

Resources

About